NASDAQ: FRTX - Fresh Tracks Therapeutics, Inc.

Yield per half year: -22.11%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Fresh Tracks Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.

more details
The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2022-09-08
ISIN US10802T2042
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.frtx.com
Цена ао 0.88
Change price per day: -1.33% (0.75)
Change price per week: 0% (0.74)
Change price per month: +2.78% (0.72)
Change price per 3 month: +1.37% (0.73)
Change price per half year: -22.11% (0.95)
Change price per year: -15.91% (0.88)
Change price per 3 year: 0% (0.74)
Change price per 5 year: 0% (0.74)
Change price per 10 year: 0% (0.74)
Change price per year to date: 0% (0.74)
All parameters

Underestimation

Title Value Grade
P/S 0.5982 10
P/BV 0.4823 10
P/E 0 0
EV/EBITDA 1.08 10
Total: 6.25

Efficiency

Title Value Grade
ROA, % -49.15 0
ROE, % -57.34 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 9.4

Growth impulse

Title Value Grade
Yield Revenue, % 1.34 1
Yield Ebitda, % -76.95 0
Yield EPS, % -99.75 0
Total: 0.2
More

Institutions Volume Share, %
JBF Capital, Inc. 295000 4.94
Gts Securities LLC 50100 0.84
Virtu Financial LLC 43558 0.73
Geode Capital Management, LLC 41449 0.69
Vanguard Group Inc 23060 0.39
Tower Research Capital LLC (TRC) 10224 0.17
Blackrock Inc. 4790 0.08
Blue Trust, Inc. 916 0.02
Steward Partners Investment Advisory, LLC 709 0.01
Osaic Holdings Inc 43 0



Head Job title Payment Year of birth
Mr. Albert Nicholas Marchio II CEO, CFO, Secretary & Chairman 251.83k 1952 (73 years)
Aron Aizenstat M.B.A., P.M.P. Vice President of Corporate Development & Operations N/A
Ms. Sue Fattor Head of Human Resource N/A
Dr. James S. McElvain Ph.D. Interim Head of CMC Development N/A
Mr. Aaron Fox-Collis CPA VP of Finance & Chief Accounting Officer N/A

Address: United States, Boulder. CO, 5777 Central Avenue - open in Google maps, open in Yandex maps
Website: https://www.frtx.com